Targeting eosinophils in chronic respiratory diseases using nanotechnology-based drug delivery.

Sharma, P; Dhanjal, DS; Chopra, C; Tambuwala, MM; Sohal, SS; van der Spek, PJ; Sharma, HS; Satija, S

Targeting eosinophils in chronic respiratory diseases using nanotechnology-based drug delivery.

Sharma, P Dhanjal, DS Chopra, C Tambuwala, MM Sohal, SS van der Spek, PJ Sharma, HS Satija, S

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Chem Biol Interact, 2022, 365, pp. 110050
Issue Date:: 2022-09-25

Closed Access

	Filename	Description	Size
	1-s2.0-S0009279722002551-main.pdf		5.02 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Sharma, P
dc.contributor.author	Dhanjal, DS
dc.contributor.author	Chopra, C
dc.contributor.author	Tambuwala, MM
dc.contributor.author	Sohal, SS
dc.contributor.author	van der Spek, PJ
dc.contributor.author	Sharma, HS
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.date.accessioned	2023-02-14T05:30:50Z
dc.date.available	2022-07-13
dc.date.available	2023-02-14T05:30:50Z
dc.date.issued	2022-09-25
dc.identifier.citation	Chem Biol Interact, 2022, 365, pp. 110050
dc.identifier.issn	0009-2797
dc.identifier.issn	1872-7786
dc.identifier.uri	http://hdl.handle.net/10453/166117
dc.description.abstract	Asthma, COPD, COVID-19, EGPA, Lung cancer, and Pneumonia are major chronic respiratory diseases (or CRDs) affecting millions worldwide and account for substantial morbidity and mortality. These CRDs are irreversible diseases that affect different parts of the respiratory system, imposing a considerable burden on different socio-economic classes. All these CRDs have been linked to increased eosinophils in the lungs. Eosinophils are essential immune mediators that contribute to tissue homeostasis and the pathophysiology of various diseases. Interestingly, elevated eosinophil level is associated with cellular processes that regulate airway hyperresponsiveness, airway remodeling, mucus hypersecretion, and inflammation in the lung. Therefore, eosinophil is considered the therapeutic target in eosinophil-mediated lung diseases. Although, conventional medicines like antibiotics, anti-inflammatory drugs, and bronchodilators are available to prevent CRDs. But the development of resistance to these therapeutic agents after long-term usage remains a challenge. However, progressive development in nanotechnology has unveiled the targeted nanocarrier approach that can significantly improve the pharmacokinetics of a therapeutic drug. The potential of the nanocarrier system can be specifically targeted on eosinophils and their associated components to obtain promising results in the pharmacotherapy of CRDs. This review intends to provide knowledge about eosinophils and their role in CRDs. Moreover, it also discusses nanocarrier drug delivery systems for the targeted treatment of CRDs.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Chem Biol Interact
dc.relation.isbasedon	10.1016/j.cbi.2022.110050
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology
dc.subject.classification	Toxicology
dc.subject.mesh	Asthma
dc.subject.mesh	Eosinophils
dc.subject.mesh	Humans
dc.subject.mesh	Lung
dc.subject.mesh	Nanotechnology
dc.subject.mesh	COVID-19 Drug Treatment
dc.subject.mesh	Lung
dc.subject.mesh	Eosinophils
dc.subject.mesh	Humans
dc.subject.mesh	Asthma
dc.subject.mesh	Nanotechnology
dc.subject.mesh	COVID-19 Drug Treatment
dc.subject.mesh	Asthma
dc.subject.mesh	Eosinophils
dc.subject.mesh	Humans
dc.subject.mesh	Lung
dc.subject.mesh	Nanotechnology
dc.subject.mesh	COVID-19 Drug Treatment
dc.title	Targeting eosinophils in chronic respiratory diseases using nanotechnology-based drug delivery.
dc.type	Journal Article
utslib.citation.volume	365
utslib.location.activity	Ireland
utslib.for	0601 Biochemistry and Cell Biology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
utslib.copyright.status	closed_access	*
dc.date.updated	2023-02-14T05:30:48Z
pubs.publication-status	Published
pubs.volume	365

Abstract:

Asthma, COPD, COVID-19, EGPA, Lung cancer, and Pneumonia are major chronic respiratory diseases (or CRDs) affecting millions worldwide and account for substantial morbidity and mortality. These CRDs are irreversible diseases that affect different parts of the respiratory system, imposing a considerable burden on different socio-economic classes. All these CRDs have been linked to increased eosinophils in the lungs. Eosinophils are essential immune mediators that contribute to tissue homeostasis and the pathophysiology of various diseases. Interestingly, elevated eosinophil level is associated with cellular processes that regulate airway hyperresponsiveness, airway remodeling, mucus hypersecretion, and inflammation in the lung. Therefore, eosinophil is considered the therapeutic target in eosinophil-mediated lung diseases. Although, conventional medicines like antibiotics, anti-inflammatory drugs, and bronchodilators are available to prevent CRDs. But the development of resistance to these therapeutic agents after long-term usage remains a challenge. However, progressive development in nanotechnology has unveiled the targeted nanocarrier approach that can significantly improve the pharmacokinetics of a therapeutic drug. The potential of the nanocarrier system can be specifically targeted on eosinophils and their associated components to obtain promising results in the pharmacotherapy of CRDs. This review intends to provide knowledge about eosinophils and their role in CRDs. Moreover, it also discusses nanocarrier drug delivery systems for the targeted treatment of CRDs.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166117